Latest news with #AINose
Business Insider
29-06-2025
- Business
- Business Insider
Upcoming Stock Splits This Week (June 30 to July 4)
These are the upcoming stock splits for the week of June 30 to July 4, based on TipRanks' Stock Splits Calendar. In simple terms, a stock split boosts the number of outstanding shares by issuing more to current shareholders, while keeping the company's overall market value intact. This maneuver lowers the share price, often making the stock more affordable, and therefore more appealing, to everyday investors. Don't Miss TipRanks' Half Year Sale Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. On the flip side, some companies choose a reverse stock split, merging shares rather than dividing them. This trims the total share count while raising the price per share, again without changing the company's total market worth. Reverse splits are frequently used to meet minimum price requirements on exchanges like the Nasdaq and help avoid delisting. Whether aiming to attract more investors or stay in good standing with exchanges, these corporate moves can send important signals that investors watch closely. Let's take a look at the upcoming stock splits for the week. Ainos (AIMD) – Ainos is a dual-platform AI and biotech company, developing the 'AI Nose' scent digitization platform alongside oral interferon therapeutics for rare and autoimmune diseases. On June 26, Ainos announced a 1‑for‑5 reverse stock split, aiming to lift its share price above Nasdaq's minimum. The split will take effect at market open on June 30. Helius Medical Technologies (HSDT) – Helius Medical Technologies, known for its innovative neuromodulation devices like the PoNS® platform for neurological recovery, announced a 1-for-50 reverse stock split on June 27 to maintain compliance with Nasdaq listing requirements. The split will take effect on June 30, with Helius shares set to trade on a split-adjusted basis starting July 1. APi Group (APG) – APi Group specializes in safety, specialty, and industrial services. On May 21, APG announced a 3‑for‑2 forward stock split, conceived to lower per‑share price, increase retail access, and improve liquidity. The ex‑date is July 1, with adjusted trading beginning that day. Channel Therapeutics (CHRO) – Channel Therapeutics is a pain‑treatment biotech preparing for a merger with Pelthos Therapeutics and a NYSE American uplist. On June 27, the company announced a 10‑for‑1 reverse split to comply with listing standards and support a $50 million private placement. The split is effective before market open July 1, with split‑adjusted trading under 'Pelthos Therapeutics' starting July 2. SciSparc (SPRC) – Tel Aviv–based SciSparc, a clinical-stage developer of central nervous system therapies, announced on June 24 a 1-for-21 reverse share split to raise its share price and maintain compliance with Nasdaq listing standards. The split will take effect at market open on July 3. TipRanks Stock Splits Calendar.
Associated Press
29-05-2025
- Business
- Associated Press
Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80%
Accelerating Toward Commercial Rollout as AI Nose Solves Critical Gaps in Elder Care SAN DIEGO, CA / ACCESS Newswire / May 29, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ('Ainos'), a leader in AI-powered scent digitization, announced today that its proprietary AI Nose platform achieved approximately 85% accuracy in detecting excretion odors data, an improvement from 80% previously, based on collected from 254 participant instances in Japan and Taiwan, resulting in 2119 valid entries for subsequent statistical evaluation. The milestone validates AI Nose as a deploy able solution for non-contact hygiene monitoring in long-term care (LTC) and positions Ainos to lead the emerging SmellTech category. SmellTech for Digitized, AI-Powered Long-term Care AI Nose digitizes scent into Smell IDs using MEMS gas sensors and proprietary AI models harnessing 13 years of scent data across healthcare and industrial use-cases. Its compact, embedded-ready design enables seamless integration into portable devices, ambient monitors, or robotic platforms. Ainos is aiming to address the aging population by aligning with government efforts to digitize aging care and reduce institutional burden. Ainos targets high-impact use cases in long-term care for seniors, including: Japan and Taiwan Face Alarming Demographic Pressure Japan and Taiwan are doubling down on robotic and AI-assisted care through initiatives like Society 5.0, Healthcare DX, and Taiwan's Long-Term Care 2.0. Ainos' AI Nose aims to support these national priorities by delivering precision, automation, and labor cost relief. Commercial Rollout Timeline Ainos is also partnering with Japan's leading service robotics company to embed AI Nose into autonomous robots, bringing olfaction into smart care infrastructure for the first time. SmellTech: A $76.5B Opportunity by 2032 Ainos is pioneering SmellTech as a new category of machine perception. The global electronic nose market is forecast to grow from $29.8B in 2025 to $76.5B by 2032, at a 14.4% CAGR, with growing use in healthcare. With solid validation, real-world deployment in progress, and deep IP, Ainos is positioned to capture first-mover advantage in this rapidly scaling sector. Human-Centric Vision and Corporate Responsibility 'I believe AI Nose is a new sensory layer for healthcare,' said Chun-Hsien (Eddy) Tsai, Chairman, President and CEO of Ainos. 'We design this platform to meet real human needs: protecting dignity, reducing labor pressure, and enabling smarter aging care. With Japan and Taiwan both facing demographic cliffs, this milestone proves that smell-driven automation can be a game-changer.' While Ainos pursues innovation and commercialization, the development of its bio-inspired electronic nose technology is fundamentally guided by a humanitarian mission. The company is dedicated to enhancing the quality of life for the elderly, alleviating long-term societal care burdens, and promoting dignity and harmony within caregiving environments and families. 'We may be a technology company, but our purpose is deeply human,' said Tsai. 'AI Nose represents more than a breakthrough in digital scent-it's Ainos' promise to confront the aging crisis with compassion and to protect the dignity of those we love.' About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Associated Press
30-04-2025
- Business
- Associated Press
Ainos Forms Partnership with ASE's Key Site to Power AI-Driven SmellTech in Semiconductor Smart Manufacturing
Expanding AI Nose's Commercial Opportunity for Smarter, Safer, and More Sustainable Factories SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 30, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ('Ainos' or the 'Company'), a leader in AI-driven scent digitization, has announced it has formed a strategic partnership with ASE Chung Li ('ASECL') - a key site of Advanced Semiconductor Engineering, Inc., the world's leading provider of semiconductor assembly and test services. This new milestone expands the joint effort to power AI scent digitization in smart manufacturing. Under a legally binding Memorandum of Understanding (MOU), Ainos and ASECL aims to first optimize AI Nose for ASECL's environment, then strategize to deploy AI Nose in ASECL's operation. ASECL, a member of the ASE Group, delivers comprehensive semiconductor manufacturing services, including engineering test, package design, IC assembly, wafer probing, final test, and design manufacturing services (DMS). Unlocking a New Dimension in Smart Manufacturing Despite the growing sophistication of semiconductor fabs, airborne VOCs (volatile organic compounds) remain a largely untapped source of process insight. These compounds can subtly impact yield, equipment health, and worker safety. Ainos' AI Nose transforms VOC patterns into real-time 'Smell ID' data-enabling intelligent monitoring, predictive analytics, and ESG compliance at scale. How AI Nose Will Enhance Smart Factory Operations: About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. About ASE Advanced Semiconductor Engineering, Inc. (ASE), a member of ASE Technology Holding Co., Ltd. (NYSE: ASX, TAIEX: 3711) is the leading global provider of semiconductor manufacturing services in assembly and test. Alongside a broad portfolio of established assembly and test technologies, ASE is also delivering innovative VIPack™, advanced packaging, and system-in-package solutions to meet growth momentum across a broad range of end markets, including AI, automotive, 5G, high-performance computing, and more. To learn about our advances in SiP, fanout, MEMS and sensor, flip chip, and 2.5D, 3D and TSV technologies, all ultimately geared towards applications to improve lifestyle and efficiency, please visit: ASE Website, or follow ASE on LinkedIn & X: @aseglobal. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Associated Press
14-04-2025
- Business
- Associated Press
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan
Dual Trials Accelerate VELDONA® Toward Rare Disease Market Entry Bridging Strategy Aims to Fast-Track U.S. Regulatory Approvals SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (Nasdaq:AIMD, AIMDW) ('Ainos' or the 'Company'), pioneer of low-dose oral interferon therapeutics, today announced significant progress in advancing its oral interferon drug platform, VELDONA® in the rare disease space. The Taiwan Food and Drug Administration (TFDA) has approved the Company's clinical trial for human immunodeficiency virus (HIV)-related oral warts, while Institutional Review Board (IRB) clearance has been granted for its upcoming Sjögren's Syndrome (pSS) study. The upcoming Taiwan trials will be conducted using the Company's next-generation VELDONA® formulation, aiming to confirm efficacy equal to or better than previous results, as well as accelerating US and Taiwan regulatory approval and commercialization. 'The upcoming Taiwan trials using our new formulation aim to confirm efficacy equal to or better than previous results. We are also pursuing bridging consultations with both Food and Drug Administration (FDA) and TFDA. If regulators confirm alignment, we could accelerate market entry through a harmonized approval process. Our partnership with Taiwan Tanabe Seiyaku for manufacturing and market development of our pSS program further strengthens our commercialization pathway,' said Chun-Hsien (Eddy) Tsai, Chairman, President, and CEO of Ainos. 'Ainos is steadily advancing across three core growth pillars: scent digitization with AI Nose technology, AI-powered point-of-care testing powered by AI Nose, and VELDONA®. These strategic pillars form a foundation to our growth. We're executing rapidly and building momentum across the VELDONA® platform. Our ability to launch two Taiwan trials in parallel reflects our dedication to capital efficiency, operational strength and delivering innovative, patient-friendly therapies to the market,' Mr. Tsai added. 'HIV-related oral warts and primary Sjögren's Syndrome both lack effective standard treatments and impose meaningful burdens on quality of life. As an oral therapy, VELDONA® provides a convenient, non-invasive alternative to injectable interferons-especially important for chronic or immune-compromised patients. We believe our previous Phase II and III trials delivered positive results, and we see significant potential for VELDONA® in these indications,' said Dr. Albert Yu, Technical Director of Pharmaceuticals at Ainos. These studies expand Ainos' immunotherapy footprint in underserved rare disease segments, in line with the Company's previously announced development plans. TFDA Approves HIV Oral Warts Trial; Enrollment to Begin in June Ainos' planned trial, titled 'Evaluation of Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-Seropositive Subjects Receiving Combination Anti-Retroviral Therapy' (Protocol ID: 03HUHI19), will be conducted at National Taiwan University Hospital (NTUH). Oral warts are a frequent and painful complication in HIV-positive patients. According to UNAIDS, approximately 39.9 million people globally live with HIV in 2023, with 1.3 million new infections and 630,000 AIDS-related deaths reported that year. Despite prevalence, oral wart treatment remains a poorly addressed niche with limited therapeutic options. The market for managing HIV-related HPV manifestations, including oral warts, is estimated at $500-700 million globally, driven by demand for safer and more tolerable long-term treatments1. Ainos plans to begin the trial in June 2025 and targets completion in 2H 2026. Primary and secondary endpoints will evaluate the efficacy of VELDONA® plus antiretroviral therapy compared to placebo. Bestat Pharmaservices Corporation, a TFDA-accredited contract research organization (CRO), will manage the study under Good Clinical Practice (GCP) standards. IRB Clears Sjögren's Syndrome Trial; TFDA Review in Progress The planned trial, titled 'An Open-Label Study to Evaluate the Efficacy Of VELDONA® in Patients with Primary Sjögren's Syndrome' (Protocol ID: 24PSS01) received IRB approval from Taipei Medical University - Joint IRB on October 25, 2024 (Approval No.: TMU-JIRB N202408042). TFDA submission is underway, with clearance expected in August 2025. Sjögren's Syndrome is a chronic autoimmune disease affecting salivary and tear glands, with limited treatment options. According to National Center for Biotechnology Information (NCBI), the condition affects an estimated 400,000 to 3.1 million people in the U.S. alone, mostly women aged 45-55. The global market for Sjögren's Syndrome therapeutics is projected to reach about $3.3 billion by 2030, driven by rising prevalence and increasing demand for effective therapies2. The trial will take place at Shuang Ho Hospital and evaluate whether VELDONA® improves salivary flow and alleviates dryness symptoms. Secondary endpoints include ESSPRI/ESSDAI scores, symptom-specific VAS ratings, and salivary gland imaging. Ainos aims to initiate site initiation visit (SIV) and first patient first visit (FPFV) in October 2025 and targets to conclude the trial in 1H 2027. ComboTrial Consultancy Ltd, a TFDA-recognized CRO, will manage the trial. Ainos has previously completed three U.S. clinical trials evaluating VELDONA® in pSS. Results showed significant improvement in oral dryness with a favorable safety profile. VELDONA®: Transforming Immunotherapy Through Oral Delivery Harnessing nearly four decades of development, VELDONA® is Ainos' proprietary low-dose oral interferon-alpha platform, designed to activate immune responses via oromucosal delivery. The platform delivers therapeutic benefit at ultra-low doses, minimizing systemic side effects often associated with injectable interferons. By targeting rare and underserved indications, Ainos is positioning VELDONA® as a versatile, scalable solution for chronic autoimmune and infectious diseases across global markets. [1]: Market scope estimate based on various analysis of HPV/HIV co-infection treatment segments. [2]: Market Report Analytics, 'Sjogrens Syndrome Therapeutics Market CAGR Growth Drivers and Trends: Forecasts 2025-2033.' About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify Ainos' commitment to enabling AI with the ability to smell and individuals to live healthier. Ainos' clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. For more information, visit: Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Associated Press
07-03-2025
- Business
- Associated Press
Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here
Practical partnership for AI Nose, multiple new opportunities AI Nose to change robotics landscape with first AI smell sensing SAN DIEGO, CA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ('Ainos' or the 'Company'), a pioneer of smell digitization, today announced that Water Tower Research ('WTR') has published a report on the Company's strategic partnership with ugo, Inc., a leading Japanese service robotics company. The collaboration will integrate Ainos' innovative AI Nose technology into ugo's service robots, marking a milestone in digitizing olfactory sensing. Key Highlights from the Report: AI Nose Integration into Robots: This partnership will elevate robotic capabilities in industrial safety, public security, environmental monitoring, and healthcare. Both companies will jointly design AI Nose-enabled robots for various industries, open revenue opportunities in multiple sectors. This is a Practical Partnership: ugo develops and commercialized next-generation avatar robots and leads Japan's service robot market share. Its robots are used in commercial buildings, data centers, factories, and public facilities, addressing Japan's workforce shortage caused by aging population. Ainos' collaboration with an established player for autonomous robots provides direct commercial access to the end-user market, rather than with a startup still in the concept stage. Elevating Robot Functionality: ugo's robots are already equipped with advanced AI-driven features, such as collision detection sensors, AI-powered image recognition, and environmental sensors for heat mapping and humidity measurement. ugo's robots are practical and commercially viable, unlike many others that are still under development and remain costly. The Final Sense for Robots-AI Smell is Here: While vision, sound, and touch have seen significant advancements in robotics, the sense of smell has remained an untapped sensory capability. AI Nose represents a breakthrough in olfactory sensing, becoming one of the first technologies to offer robots the ability to smell. This new capability positions Ainos at the forefront of a rapidly evolving industry. Japan is a Key Market in a Multi-Billion Market Opportunity: Asia dominates the global robotics market, with China and Japan ranking among the top four for installed industrial robots, robotics innovation, and service robot production. Japan is a global leader in robotics, accounting for 38% of worldwide robot production in 2023. The service robot market in Japan is projected to reach $1.2 billion by 2025, compared to $9.7 billion in the U.S. and $40.6 billion globally. New Opportunities: Ainos' partnership with ugo unlocks significant opportunities across multiple sectors, including healthcare as well as industrial and public safety. The companies expect to begin integration this year, with commercial deployment anticipated as early as 2026. This partnership is poised to accelerate innovation in smart manufacturing and safety monitoring, with far-reaching implications for the robotics industry. Link to the WTR report About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit Follow Ainos on X, formerly known as Twitter, ( @AinosInc) and LinkedIn to stay up-to-date. About ugo, Inc. ugo, Inc. is a developer of business digital transformation robots. 'ugo' is a next-generation avatar robot that realizes a sustainable work style with humans and robots. By combining the advantages of both conventional simple remote-controlled robots and fully automated robots, it provides operations that fit the site. ugo was founded in 2018 and headquartered in Tokyo, Japan. For more information, visit website or its X ( @ugo_robot). Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
